Introduction {#s1}
============

The galectin family is a group of glycan-binding proteins characterized by conserved carbohydrate recognition domains (CRDs) that bind glycosylated proteins. Galectins are involved in various processes including embryonic development, tumor biology and regulation of the immune system [@pone.0065616-Kishore1]. Within this family, Galectin-9 (Gal-9) has gained attention as a multifaceted player in adaptive and innate immunity, in particular in T-cell development and homeostasis [@pone.0065616-Wiersma1]. The most prominent effects reported for Gal-9 are the induction of apoptosis in subsets of differentiated T-cells, particularly in CD4^+^ T-helper 1 (T~H1~) and T-helper 17 (T~H17~) cells [@pone.0065616-Zhu1], [@pone.0065616-Kashio1], [@pone.0065616-Wang1], [@pone.0065616-Oomizu1], [@pone.0065616-Bi1], and a stimulatory effect on regulatory T-cell (T~reg~) activity [@pone.0065616-Oomizu1], [@pone.0065616-Wang2]. In view of these immunomodulatory effects, Gal-9 has been tested as a potential therapeutic agent for various autoimmune diseases. Treatment with Gal-9 ameliorated disease in mouse models of experimental autoimmune encephalomyelitis [@pone.0065616-Zhu1], arthritis [@pone.0065616-Seki1] and diabetes [@pone.0065616-Chou1], [@pone.0065616-Kanzaki1], by reducing the number of autoreactive T~H1~ and T~H17~ cells and decreasing circulating IFN-γ concentrations. In contrast, treatment with Gal-9 stimulated anti-tumor T-cell immune responses in a sarcoma bearing mouse model [@pone.0065616-Nagahara1]. Here, recombinant Gal-9 induced cytotoxic T-cells (CTLs) and increased IFN-γ concentrations. In addition, in a recent study focused on food-allergy treatment of *ex vivo* activated human T-cells with Gal-9 promoted T~H1~ generation as well as IFN-γ production [@pone.0065616-deKivit1]. These data imply that Gal-9 can have a Janus-like dual activity; inhibiting immunity in autoimmune disease on the one side and stimulating immunity in cancer and allergy on the other side.

The immunomodulatory effects of Gal-9 were initially attributed to signaling via T-cell immunoglobulin and mucin domain-3 (TIM-3) [@pone.0065616-Zhu1], a prominent T-cell inhibitory receptor and a marker for T-cell exhaustion that is currently being evaluated as a target for antibody-based therapy in cancer [@pone.0065616-Anderson1]. However, it has become clear that, aside from TIM-3, Gal-9 can signal via other receptors on T-cells [@pone.0065616-Su1], like protein disulfide isomerase [@pone.0065616-Bi2], [@pone.0065616-Elahi1], CD40 [@pone.0065616-Vaitaitis1] and possibly other, yet unidentified receptors. Indeed, the outcome of Gal-9 signaling on T-cells likely depends on the specific receptor being activated by Gal-9 as well as the presence of additional (T-cell) skewing stimuli. In this respect, most experimental murine autoimmune models used to evaluate therapeutic effects of Gal-9 rely on specific antibodies or disease inducing peptides in combination with infection stimulating adjuvants and/or bacteria [@pone.0065616-Zhu1], [@pone.0065616-Arikawa1], [@pone.0065616-Seki1]. In contrast, the CTL stimulatory effects via dendritic cell (DC) activation and induction of IFN-γ found in a sarcoma did not require additional skewing stimuli [@pone.0065616-Nagahara1]. Together, this suggests that the outcome of Gal-9 signaling varies greatly, depending on experimental conditions and/or the balance of immunity in specific disease settings.

Here, we aimed to establish the effect of Gal-9 treatment on freshly isolated and non-skewed human peripheral blood immune cells in the absence of other stimuli. In line with current thinking, Gal-9 triggered cell death in \>95% of T-cells at high concentrations. However, at lower doses, Gal-9 activated and strongly expanded surviving T-cells in a TIM-3-independent manner. In addition, the T-cell expansion induced by Gal-9 was characterized by a shift from a naïve towards a central memory (T~cm~) and IFN-γ producing T~H1~ phenotype. Further, a shift in monocytes towards a DC-phenotype was detected. However, monocyte depletion did not affect T-cell activation, indicating that Gal-9 had a direct effect on T-cells. In the presence of anti-CD3/IL-2 T-cell activation signals, Gal-9 did not trigger expansion of T-cells, but shifted the normal CD8/CD4 balance towards a predominant CD4^+^ phenotype. Taken together, these data indicate that Gal-9 has diverse immunomodulatory effects depending on concentration and skewing signals available and is therefore likely to have a disease-specific role that needs to be evaluated in depth for both autoimmunity and cancer.

Materials and Methods {#s2}
=====================

Antibodies & reagents {#s2a}
---------------------

The following fluorophore-conjugated anti-human antibodies from Immunotools (Friesoythe) were used in this study; anti-CD3-FITC (MEM-57), anti-CD3-Dy647 (MEM-57), anti-CD4-PE (MEM-241), anti-CD4-PE/Dy647 (MEM-241), anti-CD8-Pe/Dy47 (MEM-31), anti-CD14-Dy647 (MEM-15), anti-CD19-APC (LT19), anti-CD25-PE (MEM-181), anti-CD62L-FITC (LT-TD180). The following anti-human antibodies were from eBioscience; anti-CD8-PEcy7 (RPA-T8), anti-CD45RO-APC (UCHL1), anti-CD56-APC (MEM188), anti-TIM-3-APC (F38-2E2), anti-PD-1-PERCP (eBioI105), anti-CCR7-PerCP-Cy5.5 (3D12), anti-FoxP3-APC (236A/E7), anti-IL-2-PERCP-Cy5.5 (MQ1-17H12), anti-IL-4-PE-Cy7 (8D4-8), anti-IFNy-PERCP-Cy5.5 (4S-B3), and anti-IL-17-PERCP-Cy5.5 (eBio64DEC17). The anti-CD3-CyQ antibody was from IQ-products (IQP-519C). Streptavidin-Alexa488 was from Invitrogen. Recombinant Gal-9 (truncated form Gal-9(0)) and the physiologically occurring short isoform of Gal-9 (Gal-9(S)) were produced as described before [@pone.0065616-Nishi1]. Gal-1, Gal-2, Gal-3, Gal-8 were purchased commercially (R&D systems).

Isolation of peripheral blood mononuclear cells (PBMCs) and activation of T-cells {#s2b}
---------------------------------------------------------------------------------

Peripheral blood mononuclear cells (PBMCs) were obtained from venous blood from healthy volunteers using standard density gradient centrifugation (Lymphoprep). The ethics review board of the Multi- Regional Ethics Committee approved the study (MREC 06/Q2102/56), and all blood samples were obtained with written consent from the healthy subjects. Activated T-cells were generated by culturing PBMCs with anti-CD3 mAb (0.5 µg/mL; 72 h, UCHT1, Immunotools) followed by 96 h IL-2 (100 ng/mL, Immunotools). Monocyte depletion prior to treatment was performed by magnetic-activated cell sorting (MACS) using anti-CD14-beads (Miltenyi Biotec), resulting in \>99% depletion of monocytes as verified by flow cytometry (data not shown). Cells were cultured at 37°C exposed to 21% O~2~/5% CO~2~ in X-VIVO medium (Lonza), a chemically defined and serum-free hematopoietic cell medium, or RPMI-1640 (Lonza) supplemented with 10% v/v FBS (Thermo Scientific). Cell numbers were quantified using a cell counter (Sysmex).

Flow cytometry {#s2c}
--------------

All flow cytometric analyses were performed on a BD Accuri C6 flow cytometer (BD Biosciences) and accessory CFlow Plus analysis software. Positively and negatively stained populations were calculated by quadrant dot plot analysis (for representative dot-plots of stainings see [Figures S1](#pone.0065616.s001){ref-type="supplementary-material"}--[S3](#pone.0065616.s003){ref-type="supplementary-material"}). For cell surface marker analysis with antibodies, viable cells were gated based on forward and sideward scatter plot (for example see [Figure S1B](#pone.0065616.s001){ref-type="supplementary-material"}).

Assessment of apoptosis and Gal-9 binding {#s2d}
-----------------------------------------

PBMCs were treated for 1--7 days with medium with or without the indicated concentration of Gal-9 and analyzed for apoptosis using flow cytometric staining for phosphatidylserine exposure using an Annexin-V-FITC staining kit according to the manufacturer's protocol (Immunotools). In brief, cells were washed once with calcium binding buffer, resuspended in calcium buffer with Annexin-V, incubated for 10 min at 4°C, and analyzed by flow cytometry. To determine if Gal-9 bound to PBMCs in a CRD-dependent manner, competitive binding experiments were performed in which cells were incubated with biotinylated Gal-9 for 1 h, in the presence and absence of 40 mM α-lactose, followed by 3 washes to remove excess and non-bound Gal-9. Cell surface binding was detected using streptavidin-Alexa488.

Phenotypic analyses {#s2e}
-------------------

Phenotype assessment was determined by immunofluorescent flow cytometric staining essentially as described before [@pone.0065616-Bremer1]. Briefly, distribution of cell populations was analyzed gating on peripheral blood lymphocytes from forward scatter/sideward scatter, detecting CD3^+^ and CD19^+^ populations. In addition, CD3^−^/CD19^−^ cells were gated and analyzed for CD56-PE binding. The balance of CD4 and CD8 was analyzed within the viable cell population gated from forward scatter/sideward scatter using anti-CD4-PE and anti-CD8-PEcy7. T~EM~ staining was performed on 0.5×10^6^ cells per condition by incubation of PBMCs with APC-conjugated anti-CD45RO, PERCP-Cy5-conjugated anti-CCR7, and FITC-conjugated anti-CD3 for 30 min at room temperature in the dark. Alternatively, cells were stained with FITC-conjugated anti-CD62L, CyQ-conjugated anti-CD3 and APC-conjugated CD45RO. Isotype-matched non-specific antibodies were used as negative controls. Staining was analyzed on viable cells on forward scatter/sideward scatter plot selected within the CD3^+^ cell population.

Carboxyfluorescein succinimidyl ester (CFSE) analysis {#s2f}
-----------------------------------------------------

To determine the number of cell divisions after Gal-9 treatment, a CFSE cell proliferation kit was used according to manufacturer's protocol (CellTrace™ CFSE Cell Proliferation Kit, Invitrogen). In brief, harvested PBMCs were stained with 2.5 µM CFSE in 0.1% w/v BSA/PBS for 10 min at 37°C. Subsequently, PBMCs were incubated in fresh medium for 10 min on ice and excess dye was removed by 3 washes. CFSE-stained cells were then used to establish *in vitro* cell cultures. During a time course of 7 days, cells were harvested and an additional staining was performed, incubating CFSE-labeled PBMCs with anti-CD3-Dye647, anti-CD4-PE/Dye647, anti-CD8-PE/Dye647, anti-CD19-APC or CD56-APC for 30 min at 4°C. Staining was analyzed gating on the cell populations positive for the different phenotypic cellular markers, in which their CFSE-staining pattern was detected.

T~H1~, T~H2~, T~H17~ and regulatory T-cell (T~reg~) immunofluorescence staining {#s2g}
-------------------------------------------------------------------------------

To determine the effect of Gal-9 treatment on T~H1~, T~H2~, T~H17~, PBMCs were treated for 7 days with medium supplemented with or without 15 nM Gal-9, then washed and subsequently stimulated with phorbol 12-myristate 13-acetate (PMA) for 4 h. Subsequently, cells were washed in wash buffer (PBS, 5% v/v FBS, 0.1% w/v sodium azide) and stained with FITC-conjugated anti-CD3 for 15 min at room temperature. Cells were fixed with Reagent A (Caltag) for 10 min. After washing, cells were resuspended in permeabilization Reagent B (Caltag) and labeled with PERCP-Cy5-conjugated anti-IL-2, PERCP-Cy5-conjugated anti-IL-4, PERCP-Cy5-conjugated anti-IFN-γ, or PERCP-Cy5-conjugated anti-IL-17 for 20 min in the dark. Cells were analyzed for T-cell phenotype after 2 subsequent washes with PBS. Cytokine staining was performed on CD3^+^-gated cells. T~reg~ staining was performed by cell surface staining of PBMCs with PE-conjugated anti-CD4, FITC-conjugated anti-CD3, fixation/permeabilization as for cytokine staining above, and subsequent intracellular staining for the transcription factor FoxP3 with APC-conjugated anti-FoxP3. Staining for FoxP3 was assessed within the CD3 and CD4 double-positive population of cells.

Analysis of cytokine secretion {#s2h}
------------------------------

ELISAs were used to quantify the secretion of IFN-γ and IL-17 from PBMCs treated with and without Gal-9. In brief, *in vitro* experiments were set-up as described above and supernatant of treated cells was collected at day 7. The IFN-γ (Immunotools) and IL-17 (Thermo Scientific) ELISAs were performed according to manufacturer's protocol.

Statistical analysis {#s2i}
--------------------

Statistical analysis was performed by one-way ANOVA followed by Tukey-Kramer post-test or, where appropriate, by two-sided unpaired Student's t-test using Prism software. p\<0.05 was defined as a statistically significant difference. Where indicated \*  = p\<0.05; \*\*  = p\<0.01; \*\*\*  = p\<0.001.

Results {#s3}
=======

Galectin-9 triggers cell death but also expands resting peripheral blood cells {#s3a}
------------------------------------------------------------------------------

Initial evidence suggested that the predominant effect of treatment of T-cells with Gal-9 is the induction of apoptotic cell death in T-helper 1 (T~H1~) and T-helper 17 (T~H17~) cells via the receptor TIM-3 [@pone.0065616-Zhu1]. However, flow cytometric analysis on resting PBMCs revealed that expression of TIM-3 was negligible, whereas *ex vivo* activated T-cells did express TIM-3 ([Figure 1A](#pone-0065616-g001){ref-type="fig"} and [Figure S1A](#pone.0065616.s001){ref-type="supplementary-material"}). Despite the lack of cell surface-expressed TIM-3 Gal-9 bound to resting PBMCs ([Figure 1B](#pone-0065616-g001){ref-type="fig"}). Binding of Gal-9 was inhibited in a lectin-specific manner by co-incubation with 40 mM α-lactose ([Figure 1B](#pone-0065616-g001){ref-type="fig"}), but not by an anti-TIM-3 blocking antibody (data not shown). Thus, the binding of Gal-9 was carbohydrate recognition domain (CRD)-dependent and TIM-3-independent.

![Gal-9 triggers TIM-3-independent cell death and PBMC expansion.\
**A.** Resting PBMCs were incubated with anti-TIM3-APC or isotype control antibody or **B.** with streptavidin-Alexa488, biotinylated Gal-9+streptavidin-Alexa488 in the presence or absence of α-lactose. Cell surface staining was evaluated by flow cytometry **C.** Resting PBMCs (n = 3) were treated with medium or 15 nM of recombinant Gal-9 for up to 7 days. Cell death was determined by Annexin-V staining. **D.** PBMCs (n = 8) treated as in (C) were analyzed for cell number. **E.** Resting PBMCs (n = 8) were treated as in (C) in the presence of α-lactose or sucrose, and analyzed for cell number. **F.** Resting PBMCs (n = 3) were treated with medium or 15 nM of recombinant Gal-9, Gal-1, Gal-2, Gal-3, or Gal-8 for up to 7 days, after which cell number was determined. All graphs represent mean +/− SD.](pone.0065616.g001){#pone-0065616-g001}

Treatment of PBMCs with Gal-9 at a concentration of 150 nM, falling within the previously published range, eliminated the vast majority of cells within 1 day ([Figure S1B](#pone.0065616.s001){ref-type="supplementary-material"}). However, a 10-fold lower concentration of Gal-9 (15 nM) only triggered cell death in ∼half of the cells ([Figure S1B](#pone.0065616.s001){ref-type="supplementary-material"}). Quantification of cell death during prolonged treatment of up to 7 days, revealed that the percentage of apoptotic cells in Gal-9 treated conditions gradually declined from ∼60% at day 1 to that of medium control within 4 days ([Figure 1C](#pone-0065616-g001){ref-type="fig"}). In line with this, treatment with 15 nM Gal-9 decreased cell counts compared to control at days 1--3 ([Figure 1D](#pone-0065616-g001){ref-type="fig"}). This initial depletion was followed by strong PBMC expansion, as evidenced by a 3-fold increase in cell count at day 7 from 1×10^6^ cells/ml to ∼3×10^6^ cells/ml in Gal-9 treated conditions ([Figure 1D](#pone-0065616-g001){ref-type="fig"}). This PBMC expansion by Gal-9 was inhibited by co-treatment with α-lactose, but not sucrose, and thus CRD-dependent ([Figure 1E](#pone-0065616-g001){ref-type="fig"}).

Various other immunomodulatory members of the galectin family, i.e. Galectin-8, which is a tandem-repeat Galectin like Gal-9, as well as Galectin-1, Galectin-2 (prototypic Galectins) and Galectin-3 (chimeric Galectin) did not trigger significant increase of PBMC counts at these concentrations ([Figure 1F](#pone-0065616-g001){ref-type="fig"}), nor significant induction of apoptosis (data not shown). Thus, in addition to initial induction of apoptosis, Gal-9 triggers expansion of peripheral blood cells.

Galectin-9 and the short isoform of Gal-9 (Gal-9(S)) dose-dependently activate T-cells {#s3b}
--------------------------------------------------------------------------------------

To specify the stimulatory effect of Gal-9 on the PBMC fraction, the relative proportion of T-cells, B-cells and NK-cells was analyzed in medium and Gal-9 treated PBMCs. In medium control, the percentages of all lymphocyte populations remained stable from day 0--7 ([Figure 2A](#pone-0065616-g002){ref-type="fig"}). In contrast, treatment with Gal-9 reduced the percentage of CD3^+^ positive T-cells during the first 3 days, followed by a concomitant increase in T-cells and decrease in B-cells and NK-cells from day 4 onwards ([Figure 2B](#pone-0065616-g002){ref-type="fig"}). Further, in the viable population of CD3^+^ T-cells, treatment with 15 nM Gal-9 also triggered T-cell activation, as evidenced by the upregulation of surface CD25-expression from ∼50% at day 1 to a maximum of ∼80% after 5--7 days ([Figure 2C](#pone-0065616-g002){ref-type="fig"}, representative dot-plots in [Figure S1C](#pone.0065616.s001){ref-type="supplementary-material"}). Activation of T-cells by Gal-9 was inhibited by co-treatment with α-lactose and thus CRD-dependent ([Figure 2D](#pone-0065616-g002){ref-type="fig"}). Other galectin family members did not trigger T-cell activation ([Figure S1D](#pone.0065616.s001){ref-type="supplementary-material"}). Interestingly, during this time-course, the expression of TIM-3 was induced in only 20--30% of T-cells after 4--7 days of treatment with Gal-9 ([Figure 2E](#pone-0065616-g002){ref-type="fig"}). These T-cells did not become double-positive for TIM-3 and PD-1 ([Figure S2E](#pone.0065616.s002){ref-type="supplementary-material"}), a marker profile associated with T-cell exhaustion [@pone.0065616-Zhou1]. Thus, Gal-9 interacted with T-cells via an as yet unidentified receptor, resulting in apoptosis of part of the T-cells. However, the remaining population of viable T-cells underwent activation as well as strong expansion.

![Recombinant and Gal-9(s) dose dependently activate T-cells.\
**A.** Resting PBMCs (n = 5) were incubated in medium for up to 7 days. Distribution of cell populations was analyzed every day by flow cytometry. **B.** Similar as (A), but in the presence of 15 nM Gal-9. **C.** Resting PBMCs (n = 5) treated with medium or 15 nM of recombinant Gal-9 for up to 7 days were analyzed for T-cell activation by staining for activation marker CD25. **D.** Resting PBMCs were treated as in (C) in the presence of α-lactose, after which CD25 expression was analyzed at 1 day. **E.** Resting PBMCs (n = 5) were treated as in (C) and analyzed for expression of TIM-3. **F.** PBMCs or monocyte-depleted PBMCs were treated with Gal-9 for 7 days, and analyzed for CD25 expression **G.** Resting PBMCs (n = 6) were treated with a concentration range of recombinant Gal-9 or physiologically occurring isoform Gal-9(S) for 7 days and analyzed for cell density. **H.** Resting PBMCs (n = 6) were treated as in G and CD25 expression was determined. All graphs represent mean +/-- SD.](pone.0065616.g002){#pone-0065616-g002}

In addition to lymphocytes, the isolated PBMC fraction contains monocytes. These monocytes responded to Gal-9 treatment with a marked stretching and loss of CD14 expression, indicative of a shift towards a DC-phenotype ([Figure S2A](#pone.0065616.s002){ref-type="supplementary-material"}). Importantly, depletion of monocytes from the PBMC population prior to Gal-9 treatment did not affect Gal-9-induced activation of T-cells, as determined by CD3/CD25 double staining ([Figure 2F](#pone-0065616-g002){ref-type="fig"}). Thus, although Gal-9 activated monocytes, this was not required for activation and expansion of T-cells.

In addition to recombinant Gal-9, the short isoform of Gal-9 (Gal-9(S)) was included to evaluate whether naturally occurring isoforms of Gal-9 could have similar immunomodulatory effects. Both Gal-9 and Gal-9(S) dose-dependently triggered activation and expansion of T-cells, with maximal effects of recombinant Gal-9 at 15 nM (0.5 µg/ml) and Gal-9(S) at 30 nM (1 µg/ml) ([Figure 2G and 2H](#pone-0065616-g002){ref-type="fig"}). Thus, both recombinant Gal-9 and Gal-9(S) triggered dose-dependent activation of T-cells at low concentrations.

Galectin-9 treatment results in expansion of CD4^+^ T-cells {#s3c}
-----------------------------------------------------------

The effect of treatment of T-cells with Gal-9 on cell division was evaluated by determining T-cell proliferation by CFSE staining. In control conditions, the CD3^+^ T-cells did not divide during the 7 day time-course, as evidenced by a single CFSE fluorescence peak ([Figure 3A](#pone-0065616-g003){ref-type="fig"}). In contrast, treatment with Gal-9 triggered up to 6 cell divisions within the CD3^+^ T-cell population ([Figure 3B](#pone-0065616-g003){ref-type="fig"}), with ∼7% of T-cells having divided 6 times at day 7 ([Figure 3C](#pone-0065616-g003){ref-type="fig"}). In line with the data on apoptosis and cell counts, T-cell division was first detected after 3 days of Gal-9 treatment ([Figure 3D](#pone-0065616-g003){ref-type="fig"}).

![Galectin-9 treatment expands CD4^+^ T-cells.\
**A.** Representative plot of 6 independent experiments of resting PBMCs stained with CFSE and subsequently incubated in medium for up to 7 days. At Day 7, PBMCs were harvested, stained with the T-cell marker CD3, and CFSE peak pattern was analyzed within the CD3^+^ cells by flow cytometry. **B.** Representative plot of 6 independent experiments of resting PBMCs as treated in A, but in the presence of 15 nM Gal-9. **C.** Analysis of (A) and (B) showing percentage of CD3^+^ T-cells in the respective peak of all independent experiments (mean +/− SEM). **D.** Analysis of (B) showing the number of CFSE peaks of all independent experiments. **E.** Representative plots of 3 independent experiments of resting PBMCs stained with CFSE and subsequently incubated in medium or 15 nM Gal-9 (+/− lactose) for up to 7 days. At Day 7, PBMCs were harvested, stained with the T-cell marker CD4, and CFSE peak pattern was analyzed within the CD-3^+^ cells by flow cytometry. **F.** As in (E) but stained for the T-cell maker CD8. **G.** Resting PBMCs (n = 4) were treated for up to 7 days with medium or Gal-9 and analyzed for CD4 and CD8 distribution. All graphs represent mean +/− SD unless stated otherwise.](pone.0065616.g003){#pone-0065616-g003}

Further analysis within the Gal-9 treated populations identified that most dividing T-cells were CD4^+^ (∼76% of total PBMCs at day 7, [Figure 3E](#pone-0065616-g003){ref-type="fig"}), although the remaining CD8^+^ T-cells (∼20%) also divided in the final days ([Figure 3F](#pone-0065616-g003){ref-type="fig"}). In line with this, Gal-9 treatment induced a steady increase in the percentage of CD4^+^ T-cells during the 7 day time-course, whereas the percentage of CD8^+^ T-cells initially decreased, but returned to base levels at day 7 ([Figure 3G](#pone-0065616-g003){ref-type="fig"}; representative dot-plot in [Figure S2B](#pone.0065616.s002){ref-type="supplementary-material"}). Again, Gal-9 induced effects were CRD-specific as α-lactose completely inhibited cell division in both CD4^+^ and CD8^+^ T-cells ([Figure 3E and 3F](#pone-0065616-g003){ref-type="fig"}).

Galectin-9 expands central memory and T-helper 1 cells {#s3d}
------------------------------------------------------

As Gal-9 clearly activated and expanded T-cells, the relative proportion of naïve, central memory (T~CM~), and effector memory (T~EM~) phenotypes in the PBMCs was evaluated (for representative dot-plots of staining see [Figure S2C](#pone.0065616.s002){ref-type="supplementary-material"}). As expected, the majority of T-cells in medium control were of a naïve CCR7^+^/CD45RO^−^ phenotype ([Figure 4A](#pone-0065616-g004){ref-type="fig"}). However, upon treatment with Gal-9 or Gal-9(S), the percentage of naïve T-cells was strongly and statistically significantly reduced ([Figure 4A](#pone-0065616-g004){ref-type="fig"}), with the majority of T-cells acquiring a central CCR7^+^/CD45RO^+^ memory phenotype ([Figure 4B](#pone-0065616-g004){ref-type="fig"}). This dramatic shift was confirmed by a second staining for central memory using CD62L and CD45RO, which revealed a similar increase in CD62L^+^/CD45RO^+^ T~CM~ ([Figure S2D](#pone.0065616.s002){ref-type="supplementary-material"}). In contrast, no significant changes were detected in the CCR7^−^/CD45RO^+^ T~EM~ population ([Figure 4C](#pone-0065616-g004){ref-type="fig"}).

![Gal-9 treatment of resting PBMCs shifts T-cells towards central memory and T-helper 1 phenotype.\
**A**−**C.** PBMCs were treated for 7 days with Gal-9 or Gal-9(S) after which the percentage of naïve (**A**), central memory (**B**), and effector memory (**C**) was evaluated by flow cytometry. **D**−**G**. Resting PBMCs were treated for 7 days with Gal-9 or Gal-9(S), after which T-cell cytokine production was analyzed by flow cytometry as described in M&M. The percentage of IL-2 (n = 11) (**D**), IFN-γ (**E**), IL-17 (**F**) and IL-4 (**G**) was determined. **H.** Supernatants of medium and Gal-9 (15 nM) treated PBMCs was harvested at day7 after which the amount of secreted IFN-γ and IL-17 was determined with ELISA. **I.** PBMCs (n = 11) were treated for 7 days with Gal-9 or Gal-9(S) after which the percentage of regulatory T-cells was determined. Unless indicated otherwise; (n = 12).](pone.0065616.g004){#pone-0065616-g004}

To characterize T-cells expanded by Gal-9 on a more functional level, cytokine profiles were determined in medium control and Gal-9 treated T-cells (see [Figure S3](#pone.0065616.s003){ref-type="supplementary-material"} for representative dot-plots). In line with the immunophenotyping data, there was a marked and statistically significant increase in IL-2 producing T-cells, indicative of T~CM~ cells ([Figure 4D](#pone-0065616-g004){ref-type="fig"}). In addition, treatment with Gal-9 resulted in a statistically significant increase in IFN-γ producing T-cells ([Figure 4E](#pone-0065616-g004){ref-type="fig"}), but not in IL-17 and IL-4 producing T-cells ([Figure 4F and 4G](#pone-0065616-g004){ref-type="fig"}, respectively). In line with these findings, analysis of secreted cytokines within the supernatant of Gal-9 treated cells revealed an ∼100-fold increase in IFN-γ levels compared to medium control at day 7 ([Figure 4H](#pone-0065616-g004){ref-type="fig"}). Further, a low but significant increase in IL-17 was also detected upon treatment with Gal-9 ([Figure 4H](#pone-0065616-g004){ref-type="fig"}). In line with earlier findings, treatment with 15 nM Gal-9(S) but not Gal-9 also triggered a small but statistically significant increase in regulatory T-cells (T~regs~) after 7 days ([Figure 4I](#pone-0065616-g004){ref-type="fig"}). Thus, in resting PBMCs the treatment with Gal-9 triggers a selective expansion of central memory T-cells and a predominant induction of IFN-γ-producing CD4^+^ T-cells.

T-cell receptor-mediated activation in the presence of Gal-9 shifts the balance towards CD4+ T-cells {#s3e}
----------------------------------------------------------------------------------------------------

The results above provide evidence that Gal-9 has a potent immunomodulatory effect on resting T-cells. This T~H1~-stimulatory effect is in line with a recent report in which CD3/CD28 co-stimulation of T-cells stimulated T~H1~ development [@pone.0065616-deKivit1]. To further characterize the modulatory effect of Gal-9 during T-cell receptor (TCR)-stimulation, PBMCs were stimulated with anti-CD3 antibody for 3 days, followed by IL-2 stimulation for 4 days. In the absence of Gal-9, this stimulation regime led to a slight preferential induction of CD8^+^ T-cells compared to CD4^+^ T-cells ([Figure 5A and 5B](#pone-0065616-g005){ref-type="fig"}; median CD4^+^ 42.7% vs. median CD8^+^ 47%). However, treatment with Gal-9 or Gal-9(S) induced a dramatic shift in percentages of CD8^+^ and CD4^+^ T-cells after 7 days of activation ([Figure 5A and 5B](#pone-0065616-g005){ref-type="fig"}; median CD4^+^ 86.1% vs. median CD8^+^ 7.2%). Of note, no significant increase in apoptotic cells or cell counts was detected upon treatment with Gal-9 or Gal-9(S) after 7 days of treatment (data not shown). TCR/IL-2 mediated activation of T-cells in the presence of Gal-9 shifted T-cells toward a central memory phenotype, as defined by immunophenotyping for CD45RO/CCR7 or CD45RO/CD62L ([Figure 5C](#pone-0065616-g005){ref-type="fig"}), and intracellular cytokine staining for IL-2 ([Figure 5D](#pone-0065616-g005){ref-type="fig"}). In contrast to treatment of resting PBMCs, treatment of anti-CD3/IL-2 activated T-cells with Gal-9 did not trigger an increase in the percentage of IFN-γ producing cells ([Figure 5E](#pone-0065616-g005){ref-type="fig"}). Similarly, no increase in IL-17 or IL-4 producing T-cells or regulatory T-cells was observed ([Figure 5F−H](#pone-0065616-g005){ref-type="fig"}). Taken together, TCR-mediated activation and IL-2 induced expansion of T-cells in the presence of Gal-9 shifts the T-cell response towards a CD4^+^ helper response that is further characterized by a central memory phenotype.

![Gal-9 treatment of TCR-activated T-cells reverses CD8/CD4 distribution and shifts T-cells towards a central memory phenotype.\
A−B. T-cells were activated by anti-CD3/IL-2, or additionally with 15 nM Gal-9 or Gal-9(S). After 7 days the percentage of CD4 (A) and CD8 (B) were determined by flow cytometry. C. T-cells were activated as in (A) and percentage of T-cells with central memory phenotype was determined. D−G. T-cells were activated as in A, after which T-cell cytokine production was analyzed by flow cytometry as described in M&M. The percentage of IL-2 (n = 11) (D), IFN-γ (E), IL-17 (F) and IL-4 (G) was determined. H. T-cells were activated as in (A), after which the percentage of regulatory T-cells was determined. Unless indicated otherwise (n = 12).](pone.0065616.g005){#pone-0065616-g005}

Discussion {#s4}
==========

Gal-9 is a strong modulator of T-cell immunity known for its apoptotic effects on T~H1~ and T~H17~ cells in autoimmunity, but also for its stimulatory activity on CTLs and T~H1~ cells in cancer and food allergy. These apparent diametrical outcomes of Gal-9 signaling on T-cell immunity suggests that the balance of immunomodulatory signals is crucial for Gal-9 signaling. Data presented in the current study indicate that single-agent treatment of resting PBMCs with low Gal-9 doses is, after initial apoptotic elimination, accompanied by activation and subsequent expansion of CD4^+^ T-cells. Furthermore, Gal-9 treatment shifts T-cells from a naïve to a central memory phenotype and increases the percentage of IFN-γ producing T-cells. In activated (anti-CD3/IL-2) T-cells, Gal-9 skews the CD4^+^/CD8^+^ balance towards a CD4^+^ phenotype.

As evident from the data, the reported differences in T-cell responses upon Gal-9 treatment can be partly ascribed to the amount of Gal-9 that is used. In particular, a concentration of 150 nM eliminated the vast majority of T-cells within one day, whereas a dose-response analysis demonstrated that 15--30 nM Gal-9 is the optimal concentration for T-cell stimulatory effects. In previous reports, T-cell apoptosis was induced with relatively high doses of up to 1000 nM Gal-9 [@pone.0065616-Lu1], [@pone.0065616-Zhu1]. Furthermore, a recent study using murine T-cell clones also required high Gal-9 concentrations to induce T-cell apoptosis (400 nM), whereas non-lethal doses had T-cell stimulatory effects [@pone.0065616-Su1]. In addition to concentration, most studies were designed to evaluate Gal-9 activity at relatively short incubation periods varying from 1h to 4 days [@pone.0065616-Zhu1], [@pone.0065616-Bi1], [@pone.0065616-Kashio1], [@pone.0065616-Lu1], [@pone.0065616-Wada1]. In the current study, Gal-9 effects were evaluated for up to 7 days. Notably, significant T-cell expansion in the current study was only seen after 4 days of treatment, whereas the induction of apoptosis occurred rapidly within 1 day. Of note, these effects were independent of TIM-3, as freshly isolated T-cells lacked TIM-3 expression, and only ∼35% of T-cells became TIM-3^+^ after 4-7 days of Gal-9 treatment. Such TIM-3 independent binding has been described earlier [@pone.0065616-Su1], [@pone.0065616-Oomizu1], [@pone.0065616-Zhu1], [@pone.0065616-Bi1], and several alternate binding partners have been reported, e.g. CD40 [@pone.0065616-Vaitaitis1], several adhesion molecules [@pone.0065616-Nobumoto1], [@pone.0065616-Katoh1], immunoglobulin E (IgE) [@pone.0065616-Niki1], and protein disulfide isomerase [@pone.0065616-Bi2], [@pone.0065616-Elahi1]. Whether the TIM-3 independent binding observed in the current study can be attributed to binding of Gal-9 to one of these alternate receptors, or an as yet unidentified receptor, is subject of an ongoing study.

Binding of Gal-9 to resting blood lymphocytes activated T-cells and shifted T-cell phenotype from naïve toward IL-2 producing central memory T-cells (CD62^+^/CCR7^+^/CD45R0^+^) and IFN-γ producing T~H1~ cells. This single-agent stimulatory effect of Gal-9 on resting T-cells has not been reported before and appears to contrast with published studies that describe predominant elimination of T~H1~ cells by Gal-9. However, our findings are in line with several recent reports on the stimulatory effect of Gal-9 on activated T~H1~ cells [@pone.0065616-deKivit1], [@pone.0065616-Su1], and the induction of central memory cytokines by Gal-9 upon CD3/CD40 co-stimulation in murine T-cells [@pone.0065616-Vaitaitis1]. The mechanism by which Gal-9 induces T-cell activation and proliferation is currently unknown. However, other lectins, such as concanavalin A, also potently stimulate T-cell proliferation. Concanavalin A does so by directly interacting with activating receptors, like CD3 [@pone.0065616-Palacios1]. Within the Galectin family of lectins, it has been reported that Galectin-1 can directly bind to CD3 on T-cells [@pone.0065616-Walzel1]. It was suggested that Galectin-1 mediated ligation of the CD3-complex mimics antigen-induced TCR signaling, which induces early events in T-cell activation comparable to those elicited by agonistic anti-CD3 antibodies. Therefore, it is tentative to speculate that Gal-9 interacts with activating receptors such as CD3 on the T-cell surface. This is currently subject for further study in our laboratory.

Besides direct Gal-9 effects on T-cells, indirect T-cell stimulation by Gal-9 via the activation of DCs and DC-like macrophages was reported in sarcoma and melanoma bearing mouse models [@pone.0065616-Nagahara1], [@pone.0065616-Nobumoto1]. Furthermore, Gal-9 induced the maturation of human monocyte-derived dendritic cells, resulting in IL-12, IL-2 and IFN-γ secretion [@pone.0065616-Dai1]. In line with these findings, monocytes did undergo phenotypic changes towards DC-phenotype in the current study. However, monocyte depletion did not affect the activity of Gal-9 towards resting T-cells, which suggests that Gal-9 has a direct immunostimulatory effect on T-cells. Gal-9 was also reported to enhance production of IFN-γ by NK-cells [@pone.0065616-Gleason1], but our analysis of lymphocyte distribution/activation in the current study showed only an increase in T-cells and a decrease in NK-cells. Further, a clear increase in IFN-γ producing T-cells was detected. Thus, our data suggest that IFN-γ is secreted by T-cells and not NK-cells. In addition to T~H1~ cells, a statistically significant increase in T~reg~ cells by Gal-9(S) was detected, which is in line with recent murine studies [@pone.0065616-Lv1], [@pone.0065616-Shim1].

The here reported activating effect of low dose Gal-9 on resting T-cells may be of relevance in certain human diseases. For instance, elevated Gal-9 serum levels were detected in patients with type 2 diabetes and chronic kidney disease [@pone.0065616-Kurose1]. Here, serum Gal-9 levels negatively correlated with renal function and increased along with disease progression. Of note, aberrant recruitment and activation of T-cells has been described in diabetic nephropathy [@pone.0065616-Moon1]. Hence, Gal-9 may be involved in T-cell activation, which contributes to kidney damage in diabetes type 2. In addition, dietary supplementation of pre-biotic oligosaccharides and *Bifidobacterium breve* reduced allergic symptoms in a murine model of food allergy and in infants with atopic dermatitis, as an effect of increased serum Gal-9 levels and subsequent T~H1~ and T~reg~ responses [@pone.0065616-deKivit1]. Thus, depending on type of disease and immunological environment, serum Gal-9 can have both positive and negative effects on disease progression by the activation of T-cells.

In conclusion, treatment of human resting blood T-cells with Gal-9 induces apoptosis in a substantial proportion of the cells, but also activates and expands IFN-γ producing T~H1~ cells and central memory T-cells in surviving population. In the presence of activating signals (anti-CD3/IL2), the treatment with Gal-9 does not expand T-cells, but skews the CD4^+^/CD8^+^ balance towards a CD4^+^ phenotype. This study thus uncovers the stimulatory effect of Gal-9 treatment on resting lymphocytes and highlights the complexity of immunomodulatory signaling by Gal-9 on human T-cells. Indeed, in various diseases settings the influence of Gal-9 on T-cell immunity will be determined by micro-environmental concentrations of Gal-9 and other immune modulators as well as the activation status of T-cells.
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###### 

**A.** T-cells were activated with anti-CD3 (72h) and IL-2 (96h), after which cell surface expression of TIM-3 was analyzed by flow cytometry. **B.** resting PBMCs were treated with medium, 15 nM or 150 nM of Gal-9 for 1 day. Representative fsc/ssc dot-plots of lymphocytes demonstrate that treatment with 150 nM of Gal-9 shifts cells from a viable population (see medium; left panel) to dead/fragmented distribution (150 nM Gal-9; right panel), whereas at 15 nM ∼50% of cells remain viable (15 nM Gal-9; middle panel). **C.** representative flow cytometric dot-plots of CD3/CD25 staining **D.** resting PBMCs were treated with 0-15 nM Gal-1, Gal-2, Gal-3, Gal-8 or Gal-9. **E.** representative flow cytometric dot-plots of TIM-3/PD-1 staining in which cells were pre-gated on presence of CD3.

(TIF)

###### 

Click here for additional data file.

###### 

**A.** resting PBMCs were treated with Gal-9 for 7 days after which cell surface expression of CD14 in adhered monocytic cells was analyzed by flow cytometry. **B.** representative flow cytometric dot-plots of CD4/CD8 staining, **C.** CCR7/CD45RO staining, **D.** CD62L/CD45RO staining. For B-D, cells were pre-gated on presence of CD3.

(TIF)

###### 

Click here for additional data file.

###### 

Representative flow cytometric dot-plots of **A.** CD3/IL-2 staining **B.** CD3/IFNy staining, **C.** CD3/IL-17 staining, **D.** CD3/IL-4 staining.

(TIF)

###### 

Click here for additional data file.
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